Prospects of using olokizumab in the treatment of polymyalgia rheumatica: preliminary analysis data
A. D. Meshkov,
A. L. Maslyansky,
A. V. Torgashina,
I. O. Smitienko,
P. I. Novikov,
E. P. Ilivanova,
A. L. Chudinov,
E. G. Zotkin,
A. V. Naumov,
O. N. Tkacheva https://doi.org/10.37586/2686-8636-2-2025-265-267
Abstract
BACKGROUND. Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are diseases that develop in people over 50 years of age and often require long—term glucocorticoid (GC) therapy, which is associated with a high risk of side effects. In this regard, it is emergent to search for effective steroid-sparing drugs. Interleukin-6 (IL-6) inhibitors, such as tocilizumab and sarilumab, have already proven efficiency in the treatment of PMR and GCA. However, the availability of these drugs in Russia is limited, what makes the use of a domestic IL-6 inhibitor, olokizumab, promising.
About the Authors
A. D. Meshkov
N.I. Pirogov Russian National Research University of Medical Sciences (Pirogov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Moscow
A. L. Maslyansky
V.A. Almazov National Medical Center; St. Petersburg State University, Scientific-Clinical and Educational Center of Gastroenterology and Hepatology
Russian Federation
Russian Federation
St. Petersburg
A. V. Torgashina
Federal State State Budgetary Scientific Institution Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
I. O. Smitienko
Clinic K + 31 JSC
Russian Federation
Russian Federation
Moscow
P. I. Novikov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Moscow
E. P. Ilivanova
State Budgetary Institution “Leningrad Regional Clinical Hospital”
Russian Federation
Russian Federation
St. Petersburg
A. L. Chudinov
I. I. Mechnikov NWSMU of the Ministry of Health of Russia;
St. Petersburg State Budgetary Institution “V.A. Nasonova CRH”
Russian Federation
Russian Federation
St. Petersburg
E. G. Zotkin
Federal State State Budgetary Scientific Institution Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
A. V. Naumov
N.I. Pirogov Russian National Research University of Medical Sciences (Pirogov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Moscow
O. N. Tkacheva
N.I. Pirogov Russian National Research University of Medical Sciences (Pirogov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Moscow
Review
For citations:
Meshkov A.D., Maslyansky A.L., Torgashina A.V., Smitienko I.O., Novikov P.I., Ilivanova E.P., Chudinov A.L., Zotkin E.G., Naumov A.V., Tkacheva O.N. Prospects of using olokizumab in the treatment of polymyalgia rheumatica: preliminary analysis data. Russian Journal of Geriatric Medicine. 2025;(2):265-267. (In Russ.) https://doi.org/10.37586/2686-8636-2-2025-265-267
Views:
407
Email this article 